Pharming Group NV (PHARM) — Net Asset Quality Index
Pharming Group NV (PHARM) has a Net Asset Quality Index of 55.9% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €473.79 Million minus total liabilities of €209.14 Million yields net assets of €264.64 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check asset resilience ratio of Pharming Group NV to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Pharming Group NV Net Asset Quality Index Over Time (2005–2024)
This chart shows how Pharming Group NV's Net Asset Quality Index has evolved across 20 annual periods from 2005 to 2024. As of September 2025, the index stands at 55.9%, representing net assets of €264.64 Million against total assets of €473.79 Million EUR. See Pharming Group NV current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Pharming Group NV (2005–2024)
The table below presents the year-by-year Net Asset Quality Index for Pharming Group NV from 2005 to 2024, covering 20 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see PHARM market cap.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 55.4% | €214.16 Million | €386.88 Million | €172.72 Million | ▲ +8.9 pp |
| 2023 | 46.5% | €198.05 Million | €426.34 Million | €228.28 Million | ▼ -1.6 pp |
| 2022 | 48.1% | €204.64 Million | €425.80 Million | €221.16 Million | ▼ -0.5 pp |
| 2021 | 48.6% | €192.72 Million | €396.90 Million | €204.19 Million | ▲ +4.7 pp |
| 2020 | 43.8% | €183.73 Million | €419.12 Million | €235.39 Million | ▼ -2.0 pp |
| 2019 | 45.9% | €117.26 Million | €255.63 Million | €138.38 Million | ▲ +17.1 pp |
| 2018 | 28.8% | €70.64 Million | €245.45 Million | €174.81 Million | ▲ +17.5 pp |
| 2017 | 11.3% | €22.56 Million | €199.38 Million | €176.82 Million | ▼ -10.4 pp |
| 2016 | 21.7% | €28.89 Million | €133.34 Million | €104.45 Million | ▼ -19.7 pp |
| 2015 | 41.3% | €26.06 Million | €63.06 Million | €37.00 Million | ▼ -12.2 pp |
| 2014 | 53.6% | €36.29 Million | €67.75 Million | €31.46 Million | ▲ +37.6 pp |
| 2013 | 16.0% | €6.92 Million | €43.37 Million | €36.45 Million | ▲ +61.4 pp |
| 2012 | -45.4% | €-10.12 Million | €22.28 Million | €32.40 Million | ▼ -40.6 pp |
| 2011 | -4.8% | €-1.54 Million | €32.01 Million | €33.55 Million | ▼ -31.9 pp |
| 2010 | 27.1% | €13.43 Million | €49.59 Million | €36.16 Million | ▲ +3.3 pp |
| 2009 | 23.8% | €19.07 Million | €80.07 Million | €60.99 Million | ▲ +5.1 pp |
| 2008 | 18.7% | €17.45 Million | €93.40 Million | €75.96 Million | ▼ -11.7 pp |
| 2007 | 30.3% | €50.58 Million | €166.72 Million | €116.14 Million | ▼ -32.7 pp |
| 2006 | 63.0% | €65.78 Million | €104.37 Million | €38.59 Million | ▼ -20.1 pp |
| 2005 | 83.1% | €34.04 Million | €40.96 Million | €6.93 Million | — |